€1.7bn bid for Rottapharm stalls

In May this year, the private equity houses tabled an offer to acquire 50% of Rottapharm from the founding family in a deal that valued the firm at €1.7bn.

It is understood that a complicated deal structure meant the bidders missed the deadline to conclude the transaction.

Founded in 1961 and based in Monza, Rottapharm produces Dona, a glucosamine product that improves joints, and Mucoflux, a product for heart conditions and respiratory treatment. The firm reported a €600m turnover in 2010.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Southern Europe
• Italy
• Clessidra Capital Partners